Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.71
+0.13 (2.33%)
At close: Jun 12, 2026, 4:00 PM EDT
5.61
-0.10 (-1.75%)
After-hours: Jun 12, 2026, 6:32 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.64 billion as of June 12, 2026. Its market cap has increased by 128.14% in one year.
Market Cap
1.64B
Enterprise Value
1.43B
1-Year Change
128.14%
Ranking
Category
Stock Price
$5.71
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.64B, an increase of 137.65%. That is a compound annual growth rate of 16.35%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 12, 2026 | 1.64B | 8.91% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Generate Biomedicines | 1.66B |
| Nuvation Bio | 1.66B |
| Innoviva | 1.66B |
| Sionna Therapeutics | 1.63B |
| Precigen | 1.61B |
| AbCellera Biologics | 1.61B |
| Fortrea Holdings | 1.60B |
| Syndax Pharmaceuticals | 1.59B |